{
    "clinical_study": {
        "@rank": "161713", 
        "brief_summary": {
            "textblock": "The primary objectives are a) to establish the maximum tolerated dose of gemtuzumab\n      ozogamicin in combination with cytarabine and b) to assess the safety of gemtuzumab\n      ozogamicin when given concurrently with cytarabine."
        }, 
        "brief_title": "Study Evaluating Gemtuzumab Ozogamicin in Acute Myeloid Leukemia", 
        "completion_date": {
            "#text": "April 2003", 
            "@type": "Actual"
        }, 
        "condition": "Acute Myeloid Leukemia", 
        "condition_browse": {
            "mesh_term": [
                "Leukemia", 
                "Leukemia, Myeloid, Acute", 
                "Leukemia, Myeloid"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Morphologic diagnosis of AML from bone marrow aspirate and biopsy\n\n          -  Flow cytometry, performed at the study site, must demonstrate that the patient has\n             AML that is CD33+, based on local laboratory criteria\n\n          -  Age 18 years or older for relapsed or refractory patients for Phase I of this study\n\n        Exclusion Criteria:\n\n          -  Patients with de novo AML of the M3 subtype\n\n          -  AML following an antecedent hematologic disorder (myelodysplasia or\n             myeloproliferation) of > 2 months duration\n\n          -  AML secondary to exposure to chemotherapy or radiation"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "May 17, 2002", 
        "id_info": {
            "nct_id": "NCT00037596", 
            "org_study_id": "0903B1-205"
        }, 
        "intervention": [
            {
                "intervention_name": "Gemtuzumab Ozogamicin", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "cytarabine.", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Cytarabine", 
                "Gemtuzumab"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "lastchanged_date": "February 11, 2013", 
        "official_title": "A Dose Ranging Study of the Safety and Efficacy of Gemtuzumab Ozogamicin (GO) Given in Combination With Cytarabine in Relapsed or Refractory Patients and Alder De Novo Patients With Acute Myeloid Leukemia.", 
        "overall_official": {
            "affiliation": "Wyeth is now a wholly owned subsidiary of Pfizer", 
            "last_name": "Medical Monitor, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "April 2003", 
            "@type": "Actual"
        }, 
        "removed_countries": {
            "country": "United States"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00037596"
        }, 
        "source": "Wyeth is now a wholly owned subsidiary of Pfizer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Wyeth is now a wholly owned subsidiary of Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2000", 
        "study_design": "Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2013"
    }, 
    "geocoordinates": {}
}